Stereotactic Radiosurgery: Treatment of Brain Metastasis Without Interruption of Systemic Therapy
Stereotactic Radiosurgery: Treatment of Brain Metastasis Without Interruption of Systemic Therapy
复制标题
DOI：
10.1016/j.ijrobp.2016.01.054
复制
发表时间：
2016-06-01
影响因子：
7
通讯作者：
Kleinberg, Lawrence R.
中科院分区：
文献类型：
--
作者：
Shen, Colette J.;Kummerlowe, Megan N.;Kleinberg, Lawrence R.
目的：为了评估的患病率，结果和毒性的同时交付的全身治疗与立体定向放射外科（SRS）治疗brain metabolis.Methods和Materials：我们进行了一项回顾性研究，193例患者在我们的机构与SRS治疗脑转移瘤没有事先全脑放射治疗（WBRT）在2009年和2014年之间。结果指标包括管理的同时全身治疗，骨髓抑制，神经毒性，和survival.Results：193例患者的中位年龄为61岁，共进行了291 SRS治疗。37%的SRS治疗与全身治疗同时进行，其中46%与常规骨髓抑制化疗联合，54%与靶向和免疫治疗药物联合。全身治疗和SRS治疗后骨髓抑制极轻微，淋巴细胞减少症的3-4级毒性为14%，白细胞减少症、中性粒细胞减少症、贫血和血小板减少症的毒性为4-9%。联合治疗后的神经毒性也很小，没有4级，
Purpose: To evaluate the prevalence, outcomes, and toxicities of concurrent delivery of systemic therapy with stereotactic radiosurgery (SRS) for treatment of brain metastases.Methods and Materials: We conducted a retrospective review of 193 patients treated at our institution with SRS without prior whole-brain radiation therapy (WBRT) for brain metastases between 2009 and 2014. Outcome metrics included administration of concurrent systemic therapy, myelosuppression, neurotoxicity, and survival.Results: One hundred ninety-three patients with a median age of 61 years underwent a total of 291 SRS treatments. Thirty-seven percent of SRS treatments were delivered concurrently with systemic therapy, of which 46% were with conventional myelosuppressive chemotherapy, and 54% with targeted and immune therapy agents. Myelosuppression was minimal after treatment with both systemic therapy and SRS, with 14% grade 3-4 toxicity for lymphopenia and 4-9% for leukopenia, neutropenia, anemia, and thrombocytopenia. Neurotoxicity was also minimal after combined therapy, with no grade 4 and